This review explores how #CRISPRCas9, #epigenetic modulation, somatic cell genome editing, and #RNAbasedtherapies are transforming disease prevention by enabling precise control of #genes, while addressing their technical challenges.

#OpenAccess: doi.org/10.1016/j.ge...

Arnatar Therapeutics has officially emerged from stealth.

With a $52M Series A led by Eight Roads & 3E Bioventures and ‪@fda.gov‬ #OrphanDrug + #RarePediatricDisease designations for ART4 in #AlagilleSyndrome, we’re advancing a new era of #RNABasedTherapies.‬

Learn more: https://bit.ly/4m39ec1